CADL

Bullish

Loss-Making Candel Therapeutics, Inc. (NASDAQ:CADL) Expected To Breakeven In The Medium-Term

Candel Therapeutics, Inc. (NASDAQ:CADL), a clinical-stage biopharmaceutical company, is projected by analysts to reach breakeven around 2028, turning ...

Simply Wall Street 1 week ago 0

Bearish

Candel Therapeutics 1Q 2026: Net income $(8.9)M, EPS $(0.14) — 10-Q Summary

Candel Therapeutics reported a net loss of $(8.9)M and diluted EPS of $(0.14) for Q1 2026, a significant downturn from the previous year's positive fi...

TradingView 2 weeks ago 0